Results 41 to 50 of about 20,100 (304)
BioDrugs, 2023 Background SB12 is being developed as a proposed biosimilar to eculizumab reference product (RP), a humanized monoclonal antibody (IgG2/4 kappa immunoglobulin) that binds to the human C5 complement protein.
Hyunsoo Kim +7 more
semanticscholar +1 more source
Mayo Clinic Proceedings: Innovations, Quality & Outcomes, 2022 One of the treatment options for complement-mediated thrombotic microangiopathy (CM-TMA), also known as atypical hemolytic uremic syndrome, is the administration of the C5 complement inhibitor eculizumab.
Meera Sridharan, MD, PhD +2 more
doaj
Eculizumab in Shiga toxin-producing Escherichia coli hemolytic uremic syndrome: a systematic review
Pediatric nephrology (Berlin, West), 2023 Background Infection-associated hemolytic uremic syndrome (IA-HUS), most often due to infection with Shiga toxin-producing bacteria, mainly affects young children.
P. D. de Zwart +3 more
semanticscholar +1 more source
Indian Journal of Nephrology, 2018 Eculizumab is the therapy of choice for patients with atypical hemolytic uremic syndrome (aHUS). Dosing recommendations stem from two trials: one retrospective trial (19 children and 5 infants) and one prospective trial (22 patients and 5 infants). This case report highlights the need for more precise dosing recommendations in children, particularly in
Kobrzynski, M +3 more
openaire +5 more sources
Frontiers in Medicine, 2023 Atypical hemolytic uremic syndrome (aHUS) is a rare disease caused by genetic abnormalities, infections, autoimmune diseases, drugs, and malignancies.
Sanober Sadiq, Anatoly Urisman, Onur Cil
doaj +1 more source
An Anti-C1s Monoclonal, TNT003, Inhibits Complement Activation Induced by Antibodies Against HLA. [PDF]
, 2015 Antibody-mediated rejection (AMR) of solid organ transplants (SOT) is characterized by damage triggered by donor-specific antibodies (DSA) binding donor Class I and II HLA (HLA-I and HLA-II) expressed on endothelial cells.
Fishbein, MC +7 more
core +1 more source
Journal of Korean medical science, 2023 Background Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disorder characterized by uncontrolled terminal complement activation. Eculizumab, a monoclonal antibody C5 inhibitor was introduced in Korea in 2009 and has been the standard ...
Jin Seok Kim +18 more
semanticscholar +1 more source
European Journal of Health Economics, 2023 Objectives The aim of this study was to evaluate the cost-effectiveness of ravulizumab compared with eculizumab for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) in the Netherlands.
S. Quist +4 more
semanticscholar +1 more source
Stratification of responders towards eculizumab using a structural epitope mapping strategy [PDF]
, 2016 The complement component 5 (C5)-binding antibody eculizumab is used to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical haemolytic uremic syndrome (aHUS).
Berglund, Magnus M. +6 more
core +1 more source
Meningococcemia in a vaccinated child receiving eculizumab and review of the literature
The Turkish Journal of Pediatrics, 2023 Background. Atypical hemolytic uremic syndrome (aHUS) is a rare and severe disease characterized by uncontrolled activation and dysregulation of the alternative complement pathway and development of thrombotic microangiopathy. Eculizumab, which is
Diana Üçkardeş +5 more
doaj +1 more source